Severe food allergy patients get continued access to dupilumab
NCT ID NCT06631677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program offers continued treatment with dupilumab to adults who have severe IgE-mediated food allergies and were previously treated with linvoseltamab and dupilumab in an earlier study. The goal is to provide ongoing access to the medication for those who completed the parent study. Only adults who finished the prior study without serious side effects are eligible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab
- What this could lead to
- If successful, this program could help maintain control of severe food allergies in adults who have already received initial treatment.
- What could go wrong
- This is an expanded access program, not a formal trial, so it provides limited data on long-term safety or effectiveness. It only includes a small, specific group of patients from a prior study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Are allergy pens long enough? study measures thigh depth to find out
- AI tool aims to cut allergy misdiagnosis in primary care
- Can allergy drugs help kids tolerate peanut and more?
- Boiled cashews could be key to taming cashew allergies in kids
- Could a drug combo make food allergy treatment safer?
- Heated milk ladder could speed up allergy tolerance in kids